Latest & greatest articles for baclofen

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on baclofen or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on baclofen and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for baclofen

1. Baclofen

Baclofen Top results for baclofen - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for baclofen The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

2. Intrathecal baclofen for treating spasticity in children with cerebral palsy. (Abstract)

Intrathecal baclofen for treating spasticity in children with cerebral palsy. Cerebral palsy is a disorder of movement and posture arising from a non-progressive lesion in the developing brain. Spasticity, a disorder of increased muscle tone, is the most common motor difficulty and is associated with activity limitation to varying degrees in mobility and self care.Oral baclofen, a gamma-aminobutyric acid (GABA) agonist, has been used in oral form to treat spasticity for some time, but it has (...) a variable effect on spasticity and the dose is limited by the unwanted effect of excessive sedation. Intrathecal baclofen produces higher local concentrations in cerebrospinal fluid at a fraction of the equivalent oral dose and avoids this excessive sedation.To determine whether intrathecal baclofen is an effective treatment for spasticity in children with cerebral palsy.We searched the CENTRAL, MEDLINE, EMBASE and CINAHL databases, handsearched recent conference proceedings, and communicated

2015 Cochrane

3. Baclofen (Baclocur) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption

Baclofen (Baclocur) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption Prescrire IN ENGLISH - Spotlight ''Baclofen (Baclocur°) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption'', 1 February 2020 {1} {1} {1} | | > > > Baclofen (Baclocur°) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :   (...) |   |   |   |   |   |   |   |   |  Spotlight Baclofen (Baclocur°) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption FEATURED REVIEW The GABA analogue baclofen (Baclocur°, Ethypharm), used since the 1970s as a muscle relaxant, has now been granted marketing authorisation in France for the reduction of alcohol consumption in alcohol-dependent patients in whom the other drug treatments have

2020 Prescrire

4. Comparative effectiveness of naltrexone, nalmefene, baclofen, acamprosate, and topiramate in the treatment of alcohol dependence or alcohol use disorders to reduce alcohol consumption: a systematic review and meta-analysis

Comparative effectiveness of naltrexone, nalmefene, baclofen, acamprosate, and topiramate in the treatment of alcohol dependence or alcohol use disorders to reduce alcohol consumption: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any

2017 PROSPERO

5. What is the evidence for the use of Baclofen in acute muscle spasm and in particular for acute back pain

What is the evidence for the use of Baclofen in acute muscle spasm and in particular for acute back pain What is the evidence for the use of Baclofen in acute muscle spasm and in particular for acute back pain - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document (...) across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com What is the evidence for the use of Baclofen in acute muscle spasm and in particular for acute back pain A 2003 Cochrane systematic review on muscle relaxants for non-specific low-back pain (1) reports

2012 TRIP Answers

6. Baclofen for alcohol withdrawal. Full Text available with Trip Pro

Baclofen for alcohol withdrawal. Baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane Review published in 2015, Issue 4.To assess the efficacy and safety of baclofen for people with AWS.We updated our searches of the following databases to March 2017 (...) : the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, PubMed, Embase, and CINAHL. We also searched registers of ongoing trials. We handsearched the references quoted in the identified trials, and sought information from researchers, pharmaceutical companies, and relevant trial authors about unpublished or uncompleted trials. We placed no restrictions on language.We included all randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for people

2017 Cochrane

7. Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. (Abstract)

Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. Postprandial gastroesophageal reflux (PGER) in the distal esophagus (DE) is associated with a gastric juice 'acid pocket' (AP). Baclofen reduces AP extension into the DE in healthy volunteers, in part through increased lower esophageal sphincter (LES) pressure. We aimed to verify whether baclofen also affects postprandial AP location and extent in gastroesophageal reflux disease (GERD) patients (...) . Thirteen treatment-naive heartburn-prevalent GERD patients underwent two AP studies, after pretreatment with baclofen 40 mg or placebo 30 minutes preprandially. We performed pH-probe stepwise pull-throughs (PT) (1 cm/min, LES -10 to +5 cm) before and every 30 minutes from 30 minutes before up to 150 minutes after a test meal. After the meal, both after placebo and baclofen, gastric pH significantly dropped at 30, 60, 90 minutes postprandially (P: nadir pHs of 3.9 ± 0.6, 2.3 ± 0.6, 2.1 ± 0.4; B: nadir

2017 Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus Controlled trial quality: uncertain

8. Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. (Abstract)

Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. Benzodiazepines (BDZs) have been the treatment of choice for alcohol withdrawal syndrome (AWS); however, they are associated with several side effects and also have abuse potential. In some studies, the use of baclofen has been effective in reducing symptoms of alcohol withdrawal symptoms.The objective of this study was to compare the efficacy of baclofen and benzodiazepine (lorazepam) in reducing (...) symptoms of AWS.It was a single-center, randomized, open-label study. Patients with alcohol dependence syndrome were enrolled in the study and randomized into two groups using computer-generated random table number. Baclofen (experimental group, 10 mg three times a day) and BZDs (control group, lorazepam, 8-12 mg/day in divided doses) were orally administered for reducing symptoms of alcohol withdrawal. Both groups received Vitamin B1 (100 mg/day through intramuscular route) and psychotherapeutic

2019 Indian journal of psychiatry Controlled trial quality: uncertain

9. The Effect of Intrathecal Baclofen in Dyskinetic Cerebral Palsy: The IDYS Trial Full Text available with Trip Pro

The Effect of Intrathecal Baclofen in Dyskinetic Cerebral Palsy: The IDYS Trial Intrathecal baclofen treatment is used for the treatment of dystonia in patients with severe dyskinetic cerebral palsy; however, the current level of evidence for the effect is low. The primary aim of this study was to provide evidence for the effect of intrathecal baclofen treatment on individual goals in patients with severe dyskinetic cerebral palsy.This multicenter, randomized, double-blind, placebo-controlled (...) trial was performed at 2 university medical centers in the Netherlands. Patients with severe dyskinetic cerebral palsy (Gross Motor Functioning Classification System level IV-V) aged 4 to 24 years who were eligible for intrathecal baclofen were included. Patients were assigned by block randomization (2:2) for treatment with intrathecal baclofen or placebo for 3 months via an implanted microinfusion pump. The primary outcome was goal attainment scaling of individual treatment goals (GAS T score

2019 EvidenceUpdates

10. The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury Full Text available with Trip Pro

The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury In the present study we compared the clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury. A total of 150 patients were enrolled in the present study and were divided into two groups with 75 patients in each group, receiving baclofen or tolperisone, respectively. We used Modified Ashworth Scale, Medical research council scale (...) vs Group II, 3.04 ± 0.032, p > 0.05). However, the improvement in functional outcomes was greater in group II as compared to that in group I (Group I, 59.31 ± 1.32 vs Group II, 73 ± 1.32, p < 0.05). In addition, overall efficacy coefficient was greater for group II as compared to group I (Group I, 3.6 vs Group II, 2.3, p < 0.05). Group I had more side effects compared to Group II. Compared to baclofen, tolperisone offers greater improvement in activities of daily living compared to baclofen.

2017 Saudi Pharmaceutical Journal : SPJ Controlled trial quality: uncertain

11. Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury. Full Text available with Trip Pro

Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury. Intrathecal baclofen (ITB) has been known to reduce spasticity which did not respond to oral medications and botulinum toxin treatment. However, few results have been reported comparing the effects of ITB therapy in patients with cerebral palsy (CP) and acquired brain injury. This study aimed to investigate beneficial and adverse effects of ITB bolus injection and pump therapy in patients with CP

2017 Medicine

12. Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity. Full Text available with Trip Pro

Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity. To investigate the effect of intrathecal baclofen (ITB) on function and activity in dyskinetic cerebral palsy (CP).A retrospective cohort study of records from 25 children (15 males, 10 females; mean age 10y 11mo, SD 4y 9mo). Five were classified in Gross Motor Function Classification level IV and 20 in level V. Parents were interviewed about activities in daily life, sitting, communication, pain, sleep (...) ), sitting (p<0.001), communication (p<0.001), and fine motor function (p=0.013), but no change in gross motor function. Before ITB, pain and disturbed sleep were reported. There was a reduction in pain (p=0.002) and sleep improved (p=0.004) after ITB.After ITB in individuals with dyskinetic CP, improvements were found in sitting, communication, and fine motor skills. There was a reduction in dystonia and muscle tone, and pain and sleep improved.Intrathecal baclofen can affect specific aspects

2017 Developmental Medicine and Child Neurology

13. Baclofen Withdrawal

Baclofen Withdrawal Baclofen Withdrawal Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Baclofen Withdrawal Baclofen Withdrawal Aka (...) : Baclofen Withdrawal , Baclofen Pump , Baclofen Pump Malfunction , Baclofen Intrathecal Pump II. Background is used to reduce severe spasticity (e.g. spinal cord injury, , ) Oral poorly penetrates blood brain barrier, and requires intolerable oral doses to offer effect Instead, intrathecal has fewer side effects and may be used at low dose III. Dosing 50-100 mcg/day via (up to 900 mcg) and slowly titrate to effect Small dose modifications can have significant effects on patient findings (due to direct

2018 FP Notebook

14. Alcohol dependence: the risks of high-dose baclofen

Alcohol dependence: the risks of high-dose baclofen Prescrire IN ENGLISH - Spotlight ''Alcohol dependence: the risks of high-dose baclofen '', 1 November 2018 {1} {1} {1} | | > > > Alcohol dependence: the risks of high-dose baclofen Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Alcohol dependence: the risks of high-dose baclofen With high-dose (...) baclofen, there is an increased risk of epilepsy, infection, myocardial infarction or suicidal thoughts. Baclofen has been used as a muscle relaxant since the 1970s. In France, it has also been used orally since the 2000s, at higher doses, to reduce alcohol consumption or to help maintain abstinence among alcohol-dependent patients. At present, its use in alcohol dependence is governed by a temporary recommendation for use issued by the French Health Products Safety Agency (Agence française du

2018 Prescrire

15. Effect of a Combination of Omeprazole Plus Sustained Release Baclofen Versus Omeprazole Alone on Symptoms of Patients with Gastroesophageal Reflux Disease (GERD). Full Text available with Trip Pro

Effect of a Combination of Omeprazole Plus Sustained Release Baclofen Versus Omeprazole Alone on Symptoms of Patients with Gastroesophageal Reflux Disease (GERD). Previous studies have reported the efficacy of baclofen in the treatment of Gastroesophageal Reflux Diseases (GERD). The objective of present study is to evaluate the effect of co-administration of omeprazole 20 mg/d plus sustained Release baclofen (SR baclofen) vs. omeprazole 20 mg/d plus placebo on alleviation of symptoms (...) in patients with a diagnosis of GERD. A prospective, double blind, placebo controlled trial included 60 patients with diagnosis of GERD have been done. Patients were randomly selected to receive either SR baclofen or a placebo in addition to omeprazole 20 mg/d for a period of 2 weeks. Patients were questioned regarding heartburn, regurgitation, chest pain and hoarseness at the base line and after 2 weeks. All patients tolerated the medications and no patients failed to complete the study due to adverse

2015 Iranian journal of pharmaceutical research : IJPR Controlled trial quality: predicted high

16. Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia

Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Malaysian Health Technology Assessment (MaHTAS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Malaysian Health Technology Assessment (MaHTAS). Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia. Putrajaya: Malaysian Health Technology Assessment (MaHTAS). 2014 Authors' objectives To assess the safety, effectiveness, cost-effectiveness, organizational issues related to the use of continuous ITB infusion for treatment of patients with severe spasticity or severe dystonia or having both conditions compared with conventional treatment. Authors' conclusions

2014 Health Technology Assessment (HTA) Database.

17. Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity Full Text available with Trip Pro

Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity Bensmail D, Ward AB, Wissel J, Motta F, Saltuari L, Lissens J, Cros S, Beresniak A Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of intrathecal baclofen as a first treatment in the medical management of spasticity, in France. The authors concluded that initial baclofen could be cost-effective compared with usual care. The cost and effectiveness

2009 NHS Economic Evaluation Database.

18. A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients-The ALPADIR Study. Full Text available with Trip Pro

A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients-The ALPADIR Study. Alcohol dependence is a major public health issue with a need for new pharmacological treatments. The ALPADIR study assessed the efficacy and safety of baclofen at the target dose of 180 mg/day for the maintenance of abstinence and the reduction in alcohol consumption in alcohol-dependent patients.Three hundred and twenty adult patients (158 baclofen and 162 placebo) were randomized (...) after alcohol detoxification. After a 7-week titration, the maintenance dose was provided for 17 weeks, then progressively decreased over 2 weeks before stopping.The percentage of abstinent patients during 20 consecutive weeks (primary endpoint) was low (baclofen: 11.9%; placebo: 10.5%) and not significantly different between groups (OR 1.20; 95%CI: 0.58 to 2.50; P = 0.618). A reduction in alcohol consumption was observed from month 1 in both groups, but the difference of 10.9 g/day at month 6

2018 Alcohol and alcoholism (Oxford, Oxfordshire) Controlled trial quality: uncertain

19. Oral Baclofen Withdrawal Resulting in Progressive Weakness and Sedation Requiring Intensive Care Admission Full Text available with Trip Pro

Oral Baclofen Withdrawal Resulting in Progressive Weakness and Sedation Requiring Intensive Care Admission Baclofen is a common medication used as a muscle relaxant and antispasmodic. Baclofen-withdrawal syndrome has many symptoms such as sedation, somnolence, and weakness but can include psychological symptoms. We present a 62-year-old female whose oral baclofen was not continued at a skilled nursing facility after discharge following inpatient surgery that led to the development of altered (...) mental status and respiratory insufficiency necessitating intensive care unit admission. Abrupt cessation of baclofen, no matter the mode of administration to the patient, can lead to baclofen-withdrawal syndrome.

2016 The Neurohospitalist

20. Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. (Abstract)

Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. Neuromodulators are considered potential therapeutic options for refractory gastro-oesophageal reflux-induced chronic cough.To compare the efficacy of gabapentin and baclofen in patients with suspected refractory gastro-oesophageal reflux-induced chronic cough.Two hundred and thirty-four patients with suspected refractory gastro-oesophageal reflux-induced (...) chronic cough, who failed an 8-week course of omeprazole and domperidone, were recruited into the open-labelled study and randomly assigned to receive either gabapentin (maximum daily dose of 900 mg) or baclofen (maximum daily dose of 60 mg) for 8 weeks as add-on therapy to the previous treatment. The primary end point was the successful rate of cough resolution; and the secondary end-points included cough sensitivity to capsaicin and gastro-oesophageal reflux disease questionnaire score and reported

2019 Alimentary Pharmacology & Therapeutics Controlled trial quality: uncertain